Abstract:Secreted protein acidic and rich in cysteine (SPARC) is a member of the extracellular matrix glycoprotein family that binds to calcium ions. It may bind to a variety of proteins in the extracellular matrix and also compete with cell membrane surface receptors for growth. In the present study, the relationship between SPARC expression in gastric cancer tissues and the clinicopathological characteristics and prognosis of patients with gastric cancer were systematically evaluated. A meta-analysis and bioinformatics analysis were performed using the PubMed, Chinese National Knowledge Infrastructure, Kaplan-Meier (KM)-plotter, The Cancer Genome Atlas (TCGA), Gene Expression Profiling Interactive Analysis (GEPIA), University of ALabama at Birmingham CANcer (UALCAN), Human Protein Atlas (HPA) and Timer databases. SPARC was mainly expressed in tumor mesenchymal cells. The meta-analysis indicated that SPARC expression was higher in gastric cancer tissues than in normal tissues. SPARC was associated with the degree of differentiation and distant metastasis. K-M plotter results indicated that high SPARC expression was negatively associated with overall survival, post-progression survival and progression-free survival rates of patients. According to the Oncomine, GEPIA, UALCAN and HPA databases, SPARC mRNA and protein expression was upregulated in gastric cancer vs. normal tissues and was negatively associated with poor patient prognosis. In the TCGA database, univariate analysis indicated that lymph node metastasis and distant metastasis were associated with the prognosis of patients with gastric cancer. Cox multifactorial analysis suggested that high SPARC expression, age and distant metastasis were important factors affecting the survival time of patients with gastric cancer. Analysis with the Timer database indicated that SPARC was closely associated with the proportion of 7 immune-cell infiltrates in gastric cancer. These findings indicated that high expression of SPARC may be a potential marker of tumorigenesis and metastasis in patients with gastric cancer.

SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression

SPARC: a potential target for functional nanomaterials and drugs

Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy

SPARC Expression and Prognostic Value in Non-Small Cell Lung Cancer

SPARC is a Novel Prognostic Biomarker for Ovarian Cancer and Associated with Immune Signatures and Drug Response

SPARC Overexpression Promotes Liver Cancer Cell Proliferation and Tumor Growth

Prognostic Role of Secreted Protein Acidic and Rich in Cysteine in Patients with Solid Tumors

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease

SPARC Promotes the Proliferation and Metastasis of Oral Squamous Cell Carcinoma by PI3K/AKT/PDGFB/PDGFRβ Axis

Clinicopathological and Prognostic Significance of SPARC Expression in Gastric Cancer: A Meta‑analysis and Bioinformatics Analysis

The role of SPARC expression in pancreatic cancer progression and patient survival

Research progress of secreted protein acidic and rich in cysteine expressed in carcinoma

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs

Research Progress on SPARC in Pathogenesis of Gastric Cancer

Correlation Between Secreted Protein Acidic and Rich in Cysteine Protein Expression and the Prognosis of Postoperative Patients Exhibiting Esophageal Squamous Cell Carcinoma

Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma

Macrophage-derived SPARC Attenuates M2-mediated Pro-tumour Phenotypes

Attenuation of Fibrosis in Vitro and in Vivo with SPARC Sirna

Inhibiting immune escape in lung adenocarcinoma: the role of SPARC in suppressing CD276 function

Sparc Expression in Primary Tumor and Metastatic Lymph Node of Resected Pancreatic Cancer Patients and Its Impact on Prognosis.